Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.

Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, Bursulaya B, Hernandez ED, Wu J, Prashad M, Schlama T, Liu Y, Chu A, Schmeits J, Huang DJ, Hill R, Bao D, Zoll J, Kim Y, Groessl T, McNamara P, Liu B, Richmond W, Sancho-Martinez I, Phimister A, Seidel HM, Badman MK, Joseph SB, Laffitte B, Molteni V.

J Med Chem. 2020 Feb 5. doi: 10.1021/acs.jmedchem.9b01621. [Epub ahead of print]

PMID:
31940200
2.

Targeting the NLRP3 inflammasome in inflammatory diseases.

Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E.

Nat Rev Drug Discov. 2018 Sep;17(9):688. doi: 10.1038/nrd.2018.149. Epub 2018 Aug 17.

PMID:
30116046
3.

Targeting the NLRP3 inflammasome in inflammatory diseases.

Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E.

Nat Rev Drug Discov. 2018 Aug;17(8):588-606. doi: 10.1038/nrd.2018.97. Epub 2018 Jul 20. Review. Erratum in: Nat Rev Drug Discov. 2018 Sep;17(9):688.

PMID:
30026524
4.

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).

Tully DC, Rucker PV, Chianelli D, Williams J, Vidal A, Alper PB, Mutnick D, Bursulaya B, Schmeits J, Wu X, Bao D, Zoll J, Kim Y, Groessl T, McNamara P, Seidel HM, Molteni V, Liu B, Phimister A, Joseph SB, Laffitte B.

J Med Chem. 2017 Dec 28;60(24):9960-9973. doi: 10.1021/acs.jmedchem.7b00907. Epub 2017 Dec 8.

PMID:
29148806
5.

Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling.

Chen CW, Beyer C, Liu J, Maier C, Li C, Trinh-Minh T, Xu X, Cole SH, Hsieh MH, Ng N, Althage A, Meeusen S, Pan S, Svensson EC, Seidel HM, Schett G, Gergely P, Harris JL, Distler JH.

Ann Rheum Dis. 2017 Apr;76(4):773-778. doi: 10.1136/annrheumdis-2016-210294. Epub 2017 Feb 2.

PMID:
28153829
6.

Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors.

Cheng D, Liu J, Han D, Zhang G, Gao W, Hsieh MH, Ng N, Kasibhatla S, Tompkins C, Li J, Steffy A, Sun F, Li C, Seidel HM, Harris JL, Pan S.

ACS Med Chem Lett. 2016 May 10;7(7):676-80. doi: 10.1021/acsmedchemlett.6b00038. eCollection 2016 Jul 14.

7.

Inhibition of the Inositol Kinase Itpkb Augments Calcium Signaling in Lymphocytes and Reveals a Novel Strategy to Treat Autoimmune Disease.

Miller AT, Dahlberg C, Sandberg ML, Wen BG, Beisner DR, Hoerter JA, Parker A, Schmedt C, Stinson M, Avis J, Cienfuegos C, McPate M, Tranter P, Gosling M, Groot-Kormelink PJ, Dawson J, Pan S, Tian SS, Seidel HM, Cooke MP.

PLoS One. 2015 Jun 29;10(6):e0131071. doi: 10.1371/journal.pone.0131071. eCollection 2015.

8.

(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.

Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V.

ACS Med Chem Lett. 2015 Mar 16;6(5):562-7. doi: 10.1021/acsmedchemlett.5b00050. eCollection 2015 May 14.

9.

Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists.

Azimioara M, Alper P, Cow C, Mutnick D, Nikulin V, Lelais G, Mecom J, McNeill M, Michellys PY, Wang Z, Reding E, Paliotti M, Li J, Bao D, Zoll J, Kim Y, Zimmerman M, Groessl T, Tuntland T, Joseph SB, McNamara P, Seidel HM, Epple R.

Bioorg Med Chem Lett. 2014 Dec 1;24(23):5478-83. doi: 10.1016/j.bmcl.2014.10.010. Epub 2014 Oct 13.

PMID:
25455488
10.

Discovery of structurally novel, potent and orally efficacious GPR119 agonists.

Alper P, Azimioara M, Cow C, Mutnick D, Nikulin V, Michellys PY, Wang Z, Reding E, Paliotti M, Li J, Bao D, Zoll J, Kim Y, Zimmerman M, Groessel T, Tuntland T, Joseph SB, McNamara P, Seidel HM, Epple R.

Bioorg Med Chem Lett. 2014 May 15;24(10):2383-7. doi: 10.1016/j.bmcl.2014.03.023. Epub 2014 Mar 27.

PMID:
24751443
11.

Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.

Phillips DP, Gao W, Yang Y, Zhang G, Lerario IK, Lau TL, Jiang J, Wang X, Nguyen DG, Bhat BG, Trotter C, Sullivan H, Welzel G, Landry J, Chen Y, Joseph SB, Li C, Gordon WP, Richmond W, Johnson K, Bretz A, Bursulaya B, Pan S, McNamara P, Seidel HM.

J Med Chem. 2014 Apr 24;57(8):3263-82. doi: 10.1021/jm401731q. Epub 2014 Apr 4.

PMID:
24666203
12.

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.

Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, Harris JL.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25.

13.

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY.

J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26.

PMID:
23742252
14.

Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N, Jia Y, Sarkisova Y, Kreusch A, Hood T, Lu M, Liu G, Huang S, Liu Z, Loren J, Tuntland T, Karanewsky DS, Seidel HM, Molteni V.

ACS Med Chem Lett. 2012 Jan 1;3(2):140-5. doi: 10.1021/ml200261d. eCollection 2012 Feb 9.

15.

Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.

Jacobson LH, Commerford SR, Gerber SP, Chen YA, Dardik B, Chaperon F, Schwartzkopf C, Nguyen-Tran V, Hollenbeck T, McNamara P, He X, Liu H, Seidel HM, Jaton AL, Gromada J, Teixeira S.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Dec;384(6):565-81. doi: 10.1007/s00210-011-0686-y. Epub 2011 Sep 25.

PMID:
21947251
16.

The Pediatric Hospital Medicine Core Competencies Supplement: a Framework for Curriculum Development by the Society of Hospital Medicine with acknowledgement to pediatric hospitalists from the American Academy of Pediatrics and the Academic Pediatric Association.

Stucky ER, Maniscalco J, Ottolini MC, Agrawal R, Alverson B, Ballantine A, Beauchamp-Walters J, Billman GF, Buchanan AO, Carlson DW, Chiang VW, Clemmens MR, Clute JL, Phillips SC, Dansky T, Daru J, Daud YN, DeWolfe C, Geskey JM, Hain PD, Herzog K, Hood M, Johnson KB, Johnson R, Kelly B, Kimmons HC, Li ST, Lye PS, Maniscalco J, Marcello DE 3rd, Melzer SM, Mikula MI, Mirkinson LJ, Miller CD, O'Hara C, Ottolini MC, Pate BM, Patrick D, Percelay JM, Pressel D, Rehm KP, Rhee KE, Riederer MF, Ruhlen M, Seidel HM, Sekaran A, Shadman KA, Singla V, Smith K, Sperring JL, Stryjewski G, Stucky ER, Thompson ED Jr, Turmelle M, Tynan MG, Williams RJ, Wolf H, Wu S, Zaoutis LB, Zempsky WT.

J Hosp Med. 2010 Apr;5 Suppl 2:i-xv, 1-114. doi: 10.1002/jhm.776. Review. No abstract available.

PMID:
20440783
17.

Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.

Epple R, Cow C, Xie Y, Azimioara M, Russo R, Wang X, Wityak J, Karanewsky DS, Tuntland T, Nguyêñ-Trân VT, Cuc Ngo C, Huang D, Saez E, Spalding T, Gerken A, Iskandar M, Seidel HM, Tian SS.

J Med Chem. 2010 Jan 14;53(1):77-105. doi: 10.1021/jm9007399.

PMID:
19928766
18.

Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.

Zhang G, Ren P, Gray NS, Sim T, Wang X, Liu Y, Che J, Dong W, Tian SS, Sandberg ML, Spalding TA, Romeo R, Iskandar M, Wang Z, Seidel HM, Karanewsky DS, He Y.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6691-5. doi: 10.1016/j.bmcl.2009.09.123. Epub 2009 Oct 12.

PMID:
19854052
19.

A piece of my mind. Drama in medicine?

Seidel HM.

JAMA. 2009 Jan 7;301(1):18-9. doi: 10.1001/jama.2008.942. No abstract available.

PMID:
19126803
20.

Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold.

Marsilje TH, Alper PB, Lu W, Mutnick D, Michellys PY, He Y, Karanewsky DS, Chow D, Gerken A, Lao J, Kim MJ, Seidel HM, Tian SS.

Bioorg Med Chem Lett. 2008 Oct 1;18(19):5259-62. doi: 10.1016/j.bmcl.2008.08.077. Epub 2008 Aug 26.

PMID:
18783949
21.

Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor.

Alper PB, Marsilje TH, Mutnick D, Lu W, Chatterjee A, Roberts MJ, He Y, Karanewsky DS, Chow D, Lao J, Gerken A, Tuntland T, Liu B, Chang J, Gordon P, Seidel HM, Tian SS.

Bioorg Med Chem Lett. 2008 Oct 1;18(19):5255-8. doi: 10.1016/j.bmcl.2008.08.068. Epub 2008 Aug 22.

PMID:
18778936
22.

N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.

Molteni V, Li X, Nabakka J, Liang F, Wityak J, Koder A, Vargas L, Romeo R, Mitro N, Mak PA, Seidel HM, Haslam JA, Chow D, Tuntland T, Spalding TA, Brock A, Bradley M, Castrillo A, Tontonoz P, Saez E.

J Med Chem. 2007 Aug 23;50(17):4255-9. Epub 2007 Aug 1.

PMID:
17665897
23.

A piece of my mind. On retirement.

Seidel HM.

JAMA. 2007 Jul 11;298(2):147-8. No abstract available.

PMID:
17622587
24.

NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains.

Kim MJ, Park SH, Opella SJ, Marsilje TH, Michellys PY, Seidel HM, Tian SS.

J Biol Chem. 2007 May 11;282(19):14253-61. Epub 2007 Mar 16.

25.

Peptide binding identifies an ERalpha conformation that generates selective activity in multiple in vitro assays.

Larson CJ, Osburn DL, Schmitz K, Giampa L, Mong SM, Marschke K, Seidel HM, Rosen J, Negro-Vilar A.

J Biomol Screen. 2005 Sep;10(6):590-8. Epub 2005 Aug 15.

PMID:
16103420
26.

Rethinking well-child care: lack of standardization at the beginning.

Seidel HM.

Pediatrics. 2004 Dec;114(6):1735-6; author reply 1736. No abstract available.

PMID:
15574642
27.

Poly I:CLC induction of the interferon system in mice: an initial study of four detection methods.

Poast J, Seidel HM, Hendricks MD, Haslam JA, Levy HB, Baron S.

J Interferon Cytokine Res. 2002 Oct;22(10):1035-40.

PMID:
12433283
28.

A piece of my mind. A man of his words.

Seidel HM.

JAMA. 2002 Sep 25;288(12):1445-6. No abstract available.

PMID:
12243623
29.
30.

Pharmaceutical intervention in the JAK/STAT signaling pathway.

Seidel HM, Lamb P, Rosen J.

Oncogene. 2000 May 15;19(21):2645-56. Review.

31.

Design of conditionally active STATs: insights into STAT activation and gene regulatory function.

Milocco LH, Haslam JA, Rosen J, Seidel HM.

Mol Cell Biol. 1999 Apr;19(4):2913-20.

32.

A randomized controlled trial of prenatal pediatric visits for urban, low-income families.

Serwint JR, Wilson ME, Vogelhut JW, Repke JT, Seidel HM.

Pediatrics. 1996 Dec;98(6 Pt 1):1069-75.

PMID:
8951255
33.

STAT protein complexes activated by interferon-gamma and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties.

Lamb P, Seidel HM, Haslam J, Milocco L, Kessler LV, Stein RB, Rosen J.

Nucleic Acids Res. 1995 Aug 25;23(16):3283-9.

34.

Introns and the origin of protein-coding genes.

Bertolaet BL, Seidel HM, Knowles JR.

Science. 1995 Jun 2;268(5215):1367; author reply 1367-9. No abstract available.

PMID:
7761859
35.

Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity.

Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB, Rosen J.

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3041-5.

36.

Rapid activation of the interferon-gamma signal transduction pathway by inhibitors of tyrosine phosphatases.

Lamb P, Haslam J, Kessler L, Seidel HM, Stein RB, Rosen J.

J Interferon Res. 1994 Dec;14(6):365-73.

PMID:
7897256
37.

Medical education: broadening the agenda for change.

Seidel HM, Cohen J.

Acad Med. 1994 Nov;69(11):894-5. No abstract available.

PMID:
7945685
38.

Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor.

Tian SS, Lamb P, Seidel HM, Stein RB, Rosen J.

Blood. 1994 Sep 15;84(6):1760-4.

PMID:
7521688
39.

Medical education change: a detailed study of six medical schools.

Cohen J, Dannefer EF, Seidel HM, Weisman CS, Wexler P, Brown TM, Brieger GH, Margolis S, Ross LR, Kunitz SJ.

Med Educ. 1994 Sep;28(5):350-60.

PMID:
7845253
41.

Rapid activation of proteins that interact with the interferon gamma activation site in response to multiple cytokines.

Lamb P, Kessler LV, Suto C, Levy DE, Seidel HM, Stein RB, Rosen J.

Blood. 1994 Apr 15;83(8):2063-71.

PMID:
8161777
42.

Exons as microgenes?

Seidel HM, Pompliano DL, Knowles JR.

Science. 1992 Sep 11;257(5076):1489-90. No abstract available.

PMID:
1523407
43.

On paternalism.

Seidel HM.

Pediatr Ann. 1992 May;21(5):295-9. No abstract available.

PMID:
1625944
45.

The role of National Board examinations in medical education.

Seidel HM.

Pharos Alpha Omega Alpha Honor Med Soc. 1992 Spring;55(2):12-4. No abstract available.

PMID:
1603824
46.

Synthesis of 24-heteroatom-substituted cholestanols.

Rahman MD, Seidel HM, Pascal RA Jr.

J Lipid Res. 1988 Nov;29(11):1543-8.

47.

Phosphonate biosynthesis: isolation of the enzyme responsible for the formation of a carbon-phosphorus bond.

Seidel HM, Freeman S, Seto H, Knowles JR.

Nature. 1988 Sep 29;335(6189):457-8.

PMID:
3138545
48.

Eagle-Barrett syndrome.

Dorst JP, Seidel HM.

Pediatrics. 1982 Apr;69(4):504. No abstract available.

PMID:
7070906
49.

Legal change for child health: report on a conference.

Seidel HM.

Pediatrics. 1977 Aug;60(2):251-3. No abstract available.

PMID:
887343
50.

The Johns Hopkins experience in Columbia, Maryland.

Heyssel RM, Seidel HM.

N Engl J Med. 1976 Nov 25;295(22):1225-31.

PMID:
980036

Supplemental Content

Loading ...
Support Center